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Abstract 
Introduction 
Although the variability in FVIII:C measurement is well recognised this has not been widely reported for 
post FVIII infusion samples.  
Aim/Methods 
Three samples from haemophilia A patients were distributed in a UK National External Quality 
Assessment Scheme (NEQAS) survey, each after treatment with either ReFacto AF, Kogenate FS or 
Advate. Fifty-two UK haemophilia centres performed FVIII assays using one stage  (n = 46) and 
chromogenic ( n= 10) assays. Centres calibrated assays with the local plasma standard and with  
ReFacto AF laboratory standard (RAFLS) for the ReFacto AF sample.   
Results/Conclusions 
Chromogenic assays gave significantly higher results than one stage assays ( p<0.0001, 32% 
difference)  in the post Kogenate sample but not in the post ReFacto AF ( 11% higher by chromogenic 
assay, ns) or post Advate samples ( 3% lower by chromogenic, ns) when assays were calibrated with 
plasma standards. Twenty centres used  all Instrumentation Laboratory (IL)  APTT reagents (Synthasil)/ 
IL deficient plasma/reference plasma) in the one stage assay and 15 used all Siemens reagents (Actin 
FS/Siemens deficient plasma/reference plasma); this made a significant difference to results post 
ReFacto AF (41% higher by IL reagents, p<0.0001) and Advate ( 39% higher by IL reagents, p<0.0001), 
but not Kogenate (7% higher by IL, ns) when calibrated with plasma standards. Differences between 
results obtained with different one stage assay reagents for monitoring Advate  have implications for 
dosing patients. Furthermore there was considerable inter-laboratory variation as indicated by CVs in the 
range 15-26% for chromogenic assay and 12-19% for one  stage assay results.  This study suggests 
that external quality assessment schemes should  offer  participation in post FVIII infusion schemes 
where haemophilic patients are monitored. 
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Introduction  
Replacement of FVIII in subjects with haemophilia A is an important component of successful 
management (1).  Products containing recombinant FVIII are widely used and are the recommended 
treatment of choice in some countries (2).   In some clinical settings, replacement therapy may be more 
cost effective if laboratory monitoring is utilised.   This commonly involves determination of FVIII activity 
in post infusion samples.  The assay used for potency labelling of FVIII concentrates is important since 
the labelled potency is used during clinical trials to establish efficacious dosing recommendations. Such 
recommendations are appropriate if a clinical laboratory uses an assay which gives similar results to that 
used for potency assignment, so awareness of any assay differences is important for patient 
management.  Potency assignment for FVIII products is performed using the chromogenic assay in 
Europe and one stage assay in some other regions. 
 
 
It is well known that the results of FVIII assays continue to vary between different centres worldwide (3, 
4).  There are additional issues related to the assay of post infusion samples containing full length 
recombinant FVIII since results of chromogenic FVIII assays may be 20 ± 40% higher than results of one 
stage FVIII assays  in this setting (5 ± 8).   It may be possible to obtain better agreement between results 
with different assays by the use of a concentrate standard for assay calibration (9).  A similar relationship 
occurs in relation to samples containing one particular B-domain deleted FVIII (ReFacto, Pfizer) with 
results of chromogenic assays being approximately 20-50% higher than one stage assay results for an 
early formulation (7, 10-12)  and for a later formulation (ReFacto AF) (13-15) of this concentrate.   
 
 
The assay differences relate in part  to the source of phospholipids present in the laboratory reagents 
that are used in the one stage assay (10, 16).  It has been demonstrated that, for some test systems, 
one stage assay results are in agreement with results obtained by chromogenic assays if the one stage 
assay is calibrated using a concentrate standard prepared from the same product, both with ReFacto 
and ReFacto AF ( 8,11-15 ).  An assessment of FVIII assay performance in samples containing a B-
domain deleted FVIII product from a different manufacturer reported that chromogenic FVIII assay 
  
 4 
results were up to 30% higher than results obtained by one stage techniques based on various reagent 
combinations and depending on the level of FVIII in the sample (17).   The authors concluded that 
plasma containing this concentrate could be reliably assayed without using a product specific 
concentrate standard.   
 
 
Recent guidance from SSC of ISTH, focusing largely on potency labelling of concentrates, stated that 
the optimal approach to post infusion testing of FVIII and FIX concentrates involves assay against a 
product reference material composed of the same material as that which is utilised for treatment (18) but 
recognised that this may be difficult to implement in the routine laboratory.  
 
The ReFacto AF laboratory standard is available in countries where this concentrate is in use but the 
authors are unaware of any published data on how frequently this is used in routine practice. Data 
related to its impact on results of one stage FVIII assays involve only a few types of assay reagent in a 
small number of centres (14, 15).   We therefore decided to survey UK Haemophilia centres on their 
current practice in relation to monitoring infusions of recombinant FVIII and at the same time centres 
were invited to assay FVIII in 3 samples which had been obtained from patients infused with one of 2 
different widely used full length recombinant FVIII products (Kogenate FS, Bayer  or Advate, Baxter) or a 
B-domain deleted FVIII (ReFacto AF), using either a plasma standard or the ReFacto AF laboratory 
standard  (RAFLS) for assay calibration.  All 52 centres who returned results were participants in the UK 
NEQAS Blood Coagulation Programme. 
 
Methods 
This exercise comprised 3 samples obtained from patients with haemophilia A following treatment with 
FVIII concentrates and after giving written informed consent in accordance with regulations. 
The samples used and the details of infused products are shown in Table 1. 
All samples were collected into 0.109M citrate; plasma was buffered with 0.8 g% HEPES and 1.0 g% 
glycine, and lyophilised prior to distribution through the post at room temperature. Stability of such 
samples prepared and distributed in this way is excellent (19).  Samples were sent to a total of 57 UK 
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Haemophilia centres in  2011.  Participants were asked to perform FVIII:C assays on all three samples 
using their routine method for post-concentrate samples and using their routine plasma calibrant. In the 
case of the ReFacto AF sample participants were invited to run the assay with two separate calibration 
curves ± one prepared using their routine plasma calibrant, and one using a ReFacto AF Laboratory 
Standard (RAFLS), provided by Pfizer to UK NEQAS (Blood Coagulation) and distributed with the 
samples.  Centres performing both one-stage and chromogenic assays were asked to perform both 
assays and in the case of the post ReFacto AF sample, with both calibrants. 
 
Participants were also asked to provide information with respect to the FVIII concentrates used in their 
centres, and for details of their FVIII assay procedure for patients receiving ReFacto AF and other FVIII 
products. 
 
 Statistical analysis. 
 
Results obtained by chromogenic or one stage assay were compared using an unpaired t test as were 
one stage FVIII assay results obtained by the two most commonly used commercial reagent sets 
 
Results 
Responses and factor VIII assay results were received from a total of 52 centres.   
Details of practice described below related to concentrates used and the way in which FVIII assays were 
routinely performed on samples from patients receiving each particular concentrate. 
 
Concentrates in use 
 
Details of which concentrates were in use are shown in Table 2 for the 4 most commonly used brands 
together with details of whether one stage or chromogenic FVIII assays were usually performed and 
whether assays were routinely calibrated with a plasma or concentrate standard. 
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Other products listed by participants included the following 8Y (n=6), Alphanate (n=5), Wilate (n=5), 
Fandhi (n=4), Octanate (n=3), Optivate (n=2).  Most centres routinely used more than one brand of 
concentrate and 3 or more concentrate  brands were  used in 36 centres with 8 centres using  5 or more 
brands. 
 
Assay design for analysis of post infusion samples containing ReFacto AF  
 
Of those responding to questions about assay calibration the majority routinely used the RAFLS when 
assaying post infusion samples from patients treated with ReFacto AF (Table 2).  A fresh calibration 
curve was prepared with each assay in 14/32 centres (44%) using between 3 and 8 different dilutions 
(median 5).  All but 1 centre diluted the RAFLS in buffer after making the initial pre-dilution in FVIII 
deficient plasma. The initial dilution is included to reduce the concentration of FVIII to around 100 IU/dl.  
A stored calibration curve was used by 18 centres (56%), using between 4 and 8 dilutions (median 7).  
All but 2 of these centres diluted the calibrant in buffer.   
 
Thirty of the 32 centres providing details diluted test samples in buffer, using between 1 and 3 test 
sample dilutions (median 3) with 4 centres including only a single dilution of test plasma. The other 2 
centres used FVIII deficient plasma to construct test sample dilutions 
 
 
Assay design for analysis of post infusion samples containing Kogenate FS or Advate 
concentrates   
 
A fresh calibration curve was prepared with each assay in 16/43 centres (37%), using between three and 
eight different dilutions (median six).  All but two centres diluted the calibrant in buffer.  A stored 
calibration curve was used by 27 centres ( 63%) using between five and eight dilutions (median eight).  
All but two of these centres diluted the calibrant in buffer.   
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All but five of the centres providing details diluted test samples in buffer, using between one and three 
test sample dilutions (median three) with  four centres including only a single dilution of test plasma. The 
other five centres used FVIII deficient plasma to construct test sample dilutions 
 
 
Relationship between results obtained by one stage and chromogenic FVIII assay 
 
Results of FVIII assay by one stage or chromogenic assay are summarised in Table 3. Results obtained 
by chromogenic assay were significantly greater than those obtained by one stage assay for the post-
Kogenate FS sample (difference of 32%, p< 0.0001). There was no significant difference between 
chromogenic and one stage FVIII assay results in either the post-Advate sample (3% higher by one 
stage assay) or the post- ReFacto AF sample for assays calibrated using plasma standards (11% higher 
by chromogenic assay). Analysis of the impact of using the ReFacto laboratory standard for assay 
calibration is given in other sections below. 
 
 
One stage FVIII Assay results with different reagents (plasma standards as calibrants). 
 
Two APTT reagent sets were used in FVIII assays in sufficient numbers for analysis. Twenty centres 
used Synthasil APTT reagent in combination with calibration plasma and FVIII deficient plasma from 
Instrumentation Laboratory (IL, Bedford, USA) in their one stage FVIII assay testing. At the time of the 
survey this source of FVIII deficient plasma typically contained <5 IU/dl von Willebrand Factor. There 
were 15 users of Actin FS APTT reagent in combination with calibration plasma and FVIII deficient 
plasma from Siemens (Marburg, Germany). At the time of the survey this deficient plasma typically 
contained normal or near normal levels of VWF. Results obtained using these two reagent sets are 
shown in Table 4. Results were significantly higher with IL reagents than with Siemens reagents for the 
post- ReFacto AF and post Advate samples but not for the post Kogenate FS sample. 
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Effect of ReFacto AF laboratory standard on one stage FVIII Assay results  
 
Use of the ReFacto AF laboratory standard in place of the usual plasma standard for assay calibration 
made no significant difference to one stage FVIII assay results obtained on the post- ReFacto AF sample 
when all one stage assay data were combined irrespective of reagents used. However there were 
important differences between the impact of using the RAFLS for assay calibration depending on the 
commercial source of reagents used for the one stage assay (Table 4). Use of RAFLS in place of the 
usual plasma standard for calibration made a 42% difference to FVIII assay results obtained using the 
Siemens reagent set but only a 3% difference to results obtained with the IL reagent set. There was a 41 
% difference between one stage results obtained with the 2 reagent sets when assays were calibrated 
with plasma standards which was reduced to only 5% when assays were calibrated with RAFLS  
 
 
Chromogenic FVIII Assay results with different kits. 
Use of the ReFacto AF laboratory standard in place of plasma standards made no significant difference 
to chromogenic FVIII assay results obtained on the post- ReFacto AF sample.  
 
Five different kits were used amongst the 10 centres who returned chromogenic FVIII assay results. 
Results are shown in Table 5.  Numbers were too small for statistical assessment. 
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Discussion. 
Many haemophilia centres in the UK use both full length recombinant and B domain deleted (BDD) FVIII 
products in management of haemophilia A. Both one stage and chromogenic FVIII assays are in use and 
most centres use RAFLS , a product specific concentrate standard, to calibrate FVIII assays when 
patients are receiving ReFacto AF.  We report here a survey of practice in UK haemophilia centres 
addressing which products are in use, which type of FVIII assay is performed and how these FVIII 
assays are calibrated. We also report on FVIII assays performed in 52 UK haemophilia centres on 
samples from moderate or severe haemophilia A subjects who had been infused with either Advate, 
Kogenate FS, or ReFacto AF.  
 
At the time of the survey (2011) all centres were using more than one brand of FVIII concentrate and 
36/42 respondents included ReFacto AF amongst these. In the present study all but 4 of 52 returned 
results by one stage assay. Ten of the 52 centres (19%) returned results by chromogenic FVIII assay. 
This was similar to the 23% of laboratory scientists reporting frequent use of chromogenic FVIII assays 
in their haemophilia centres in one international survey of 210 scientists from 7 countries (20). In another 
survey chromogenic FVIII assays were used in 7/13 centres whereas one stage assays were used in 
12/13  (21).  
 
The mean Factor VIII activity obtained by chromogenic assay was  significantly greater than that 
obtained by one stage techniques for the sample collected after Kogenate FS infusion ( 32% higher by 
chromogenic assay, p<0.0001) but not for the sample collected post- Advate infusion where the 
difference  was only 3% (higher by one stage assay, not significant). For the sample collected after 
ReFacto AF infusion there was no significant difference between one stage and chromogenic assay 
results irrespective of whether the assay was calibrated with the conventional plasma standard in local 
use (11% higher by chromogenic , not significant) or with RAFLS as one stage assay calibrator ( 4% 
difference, not significant).  
 
A number of other studies assessing full length recombinant FVIII in a number of different formulations 
have also reported higher results by chromogenic assay in spiked samples (10, 17) and in post infusion 
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samples from patients (5,  8,  15).  Lusher et al (5) reported that chromogenic assay results were on 
average approximately 35-40% higher than one stage. Three different APTT reagents were used in one 
stage assays and the discrepancy was greatest for the reagent containing Kaolin as activator (Lusher 
1998). Another study reported one stage FVIII assay results to be 75-80% of those obtained by 
chromogenic assays for samples containing full length recombinant FVIII (10).  A similar effect was 
reported by Hubbard and colleagues (9) for two  full length recombinant materials. Results obtained with 
chromogenic assays were 45-53% higher than those obtained with a one stage assay . This study also 
demonstrated that the difference between results obtained by chromogenic and one stage assay could 
be abolished by use of a concentrate standard for assay calibration (9). 
 
Samples containing Advate spiked into severe haemophilic plasma have been included in multi -centre 
studies of FVIII assays in relation to newer concentrates (17, 22). Both studies identified higher 
chromogenic assay results compared to one stage results when FVIII was in the 60-90 IU/dl range (by 
12-19%)  but either no difference  ( 22) or  lower (17)  chromogenic assay results for samples containing 
3-5 IU/dl FVIII.  
There was considerable inter-laboratory variation for all samples irrespective of which concentrate had 
been infused  or which standard had been used for assay calibration. This variability was higher for  
chromogenic results as indicated by CVs in the range 15-26%,  compared to CVs of 12-19% for one  
stage assay results.  Higher inter laboratory variability amongst chromogenic FVIII assay results 
compared to one stage data also occurred in samples containing advate in one inter-laboratory field 
study ( 22) though not in another (17).  High inter- laboratory variation in FVIII assays remains a 
consistent finding in external quality assessment/proficiency testing surveys ( 3, 4, 8) and field studies 
(12, 17, ) indicating that improvements in standardisation of FVIII assays are needed.  
 
Overall our finding of higher chromogenic assay results compared to one stage for the sample containing 
Kogenate FS concurs with published data whereas our finding of similar one stage and chromogenic 
result for the sample containing Advate or ReFacto AF differs to some extent from previous studies. This 
may relate to the level of FVIII present in the test material but may also be partly a consequence of the 
pattern of reagents/kits used by the centres in our study since we noted one stage assay results were 
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around 40% higher for users of Instrumentation laboratory reagents compared to results obtained by 
Siemens reagent users for both Advate and ReFacto AF.  Possible reasons for this in relation to 
ReFacto AF  are discussed below. The finding of around 40% difference between results of one stage 
assays performed with different reagents has not been previously reported for samples containing 
Advate to the best of our knowledge. The cause of this difference is unknown but could relate to the 
nature of the APTT reagent ( phospholipid/ and activator), the different deficient plasmas used ( with and 
without VWF) or error in the potency assigned to the one or both of the  plasma standards. If confirmed 
on a larger series of samples this has could impact on patient management decisions so further studies 
are required to investigate this.  
 
There are a number of studies reporting higher results for chromogenic assay compared to one stage 
assay in samples containing ReFacto  ( 8, 10, 12, 16) and ReFacto AF (14, 15).  This relationship is 
affected by the nature of the laboratory reagents used in one stage assays. For example one stage 
assay results were shown to be approximately half of those obtained by chromogenic assay using 
unmodified APTT reagents in the one stage but there was no difference when phosphatidyl serine 
content was reduced to more physiologic levels or when platelets were used as source of phospholipid 
to support clotting reactions during one stage assays (10).  In our study there was no difference between 
one stage assay results (calibrated with plasma standard) and chromogenic  assay results when one 
stage assay was performed with IL reagents, in contrast to a 40% difference (lower by one stage) when 
one stage  assays were performed  with reagents from Siemens. There are 3 main differences between 
the one stage reagent sets - namely the reference plasma, the FVIII deficient plasma, and the APTT 
reagent. Any, or all of these 3 components could have contributed to the observed pattern of results. In 
relation to reference plasma it could in theory be a consequence of inaccuracy of potency assignment to 
one or both  of the commercial standards . For the 2 FVIII deficient plasmas the most obvious difference 
at the time of the survey was the absence of VWF from IL FVIII deficient plasma compared to normal 
concentrations in the Siemens material. The two APTT reagents in question differ in their activator 
(Ellagic acid in Actin FS or silica in SynthASil) and in their phospholipid content.  The phospholipid 
content of Actin FS is strikingly different from most other APTT reagents in that is lacks phosphatidyl 
serine and has an unusually high total concentration of phospholipid (23). The lower one stage FVIII 
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assay results obtained with Actin FS in the present study are consistent with the findings of Mikaelsson 
(10)  who reported that higher phospholipid concentration in the one stage assay is associated with 
larger discrepancy compared to chromogenic assay results,  and with a study by Caron and co workers ( 
24) who restored agreement between one stage and chromogenic assay results by dilution of the APTT 
reagent and therefore the phospholipid content. 
 
An alternative and more widely used approach to restoring agreement between chromogenic and one 
stage assay in samples containing ReFactois to calibrate one stage assays with a product specific 
standard and it has been proposed that concentrate specific standards for post infusion monitoring 
should be used when recommended by the concentrate manufacturer ( 25).   This approach has been 
used to successfully abolish differences between one stage and chromogenic assay results of around 
30-40% (lower by one stage) in some studies (8, 11-15).  Recalibration of both ReFacto and the RLS 
reduced the differences between one stage and chromogenic assay results (13), though discrepancies 
have persisted following the reformulation of this particular BDD FVIII as ReFacto AF (15).  In the 
present study there was good agreement between one stage assay and chromogenic when one stage 
assays were performed with IL reagents but not when Siemens reagent were used. Thus ReFacto AF 
lab standard was needed to deliver agreement with chromogenic assay results when using Siemens one 
stage reagents but not when using the IL reagent set.  
 
Concentrates containing FVIII or FIX which has been modified to extend half life after infusion are in 
development and  in use with recommendations about potency labelling (18) and deliberations about 
discrepancies between results obtained by different assays already published (26). Some have 
suggested that the use of product specific standards may be the optimal approach (18 ) whilst 
recognising that this may be difficult to implement in the routine laboratory. Responses to our 
questionnaire about current practice are therefore of interest, not just for current use of RAFLS, but as 
an indication of whether service laboratories can routinely handle such an approach in relation to future 
developments.  We asked centres to indicate what material was used for calibration of FVIII assays. 
Most centres routinely used more than one brand of concentrate and many were using 3 or more and 
including ReFacto AF amongst these  Approximately 90% of the centres where ReFacto AF was in use 
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for treatment of patients calibrated their FVIII assays with RAFLS if the patient was receiving this brand 
of concentrate . One centre used the 8th WHO international concentrate standard for assay calibration 
when monitoring samples collected after Kogenate FS or Advate infusions. The remainder all used 
plasma standards for assay calibration. Most participants in the present exercise were therefore regularly  
using different calibrants depending on which concentrate the patient had received. 
 
In conclusion our study shows that results of FVIII assays performed after infusion of  FVIII concentrate 
depend on the assay and reagent used. After infusion of Kogenate FS results were higher for 
chromogenic assay compared to one stage assay. After infusion of Advate or ReFacto AF one stage 
results were close to chromogenic but in both cases were affected by the type of one stage assay 
reagents used. Many centres were routinely performing factor VIII assays using different calibrants 
depending on which product was being used. We believe that regular proficiency testing/external quality 
assessment of post infusion monitoring is needed and further exercises will be undertaken.  
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Tables 
 
Table 1. Post Infusion samples and concentrates used. 
  
Sample Baseline FVIII before 
infusion 
Concentrate infused Collection Time and 
dose 
1 3 IU/dl ReFacto AF 20 min post 2000U 
2 <1 IU/dl Kogenate FS 120 min post 2000U 
3 <1 IU/dl Advate  240 min post 2000U 
 
 
Table 2. Concentrates and FVIII assays used in different centres 
 
 
Product  
 Assay type in routine use for monitoring each 
product 
Material used for assay 
Calibration 
n* One 
Stage  
 
Chromogenic 
Two 
Stage 
clotting 
Both One Stage 
&  
Chromogenic 
Plasma Concentrate 
Kogenate 
FS 
31 28 1 1 1 29 1** 
 
Helixate 26 
 
24 1 1  24 1** 
ReFacto 
AF 
36 31 3 - 2 4 32*** 
 
Advate 39 
 
35 2 1 1 33 - 
 
x n = number of centres ** Full details not provided 
*** ReFacto AF laboratory standard 
(Apparent numerical discrepancies are a consequence of incomplete returns) 
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Table 3.  Summary of FVIII assay results from all centres 
 
 
ReFacto AF sample Kogenate FS Advate 
 Plasma RAFLS Plasma Plasma 
1 stage assays (n=46) 
    
Median (IU/dl) 58.3 62.6 52.0* 43.0 
CV (%) 17 19 12 17** 
Range IU/dl) 40.0-73.9 36.5-97.6 42.2-72 31.6-63.6** 
Chromogenic assays 
(n=10) 
    
Median (IU/dl) 64.9 55.0 68.6* 41.6 
CV (%) 22 26 15 19 
Range (IU/dl) 37.9-77 29.2-86.5 44.0-78 23.2-49 
 
* Significantly different, p <0.0001 
** FHQWUHUHSRUWHGUHVXOWV³XGO´IRUVDPSOHFRQWDLQLQJ$GYDWHZKLFKZDVH[FOXGHGIURPFDOFXODWLRQV
of CV 
 RAFLS ± ReFacto AF laboratory standard 
  
 21 
 
Table 4. One stage FVIII assay results calibrated with plasma standards as determined using the 2 most 
widely used reagent sets  
 
 
 
Post- ReFacto AF 
Plasma std 
 
Post- ReFacto AF 
ReFacto Lab std 
Post- Kogenate FS 
Plasma std 
Post- Advate 
Plasma std 
Reagents from IL 
Median FVIII (IU/dl)  
Range (IU/dl) 
CV  
 
63.3  
50 ± 73 
9% 
 
61.3 
36 ± 97 
25% 
 
53.4  
42 ± 59 
9% 
 
47.1 
35 ± 55 
10% 
Reagents from Siemens 
Median FVIII (IU/dl)  
Range (IU/dl) 
CV 
 
45.0 
40 ± 55 
11% 
 
64.1 
56 - 77 
9% 
 
49.7 
15 ± 58 
9% 
 
34.0 
32 ± 40 
8% 
Difference 41% 5% 7% 39% 
Unpaired t test p<0.0001 ns ns p<0.0001 
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 Table 5.  Factor VIIII results obtained with different Chromogenic assay kits  
 
Kit/Manufacturer N* FVIII (IU/dl) results 
Sample 1  
ReFacto AF 
FVIII (IU/dl) 
Sample 2 
Kogenate FS 
FVIII (IU/dl) 
Sample 3 
Advate 
Plasma 
standard RAFLS 
Plasma 
standard 
Plasma 
standard 
Biophen 2 43,77  29,56 55,73 23,49 
Coamatic 1 67 86 70 45 
Coatest 1 61 54 64 39 
Electrachrome/IL 2 72,74 50,60 68,78 44,47 
Siemens 4 38,52,63,72 49,54,58,66 44,64,69,71 36,37,37,48 
*One of the 11 chromogenic assay users in table 2 did not return results 
 
 
 
. 
 
